%0 Journal Article
%T 甲巯咪唑致肝损伤相关因素研究进展<br>Advances in the Study of Related Factors of Methimazole-Induced Liver Injury
%A 张丽芹
%J Advances in Clinical Medicine
%P 9020-9023
%@ 2161-8720
%D 2022
%I Hans Publishing
%R 10.12677/ACM.2022.12101304
%X 甲巯咪唑(MMI)是目前临床上应用最广泛的抗甲状腺药物之一，肝功能损害是其最常见的不良反应，并成为困扰临床医生治疗甲状腺功能亢进的难关。本文对药物性肝损伤(DILI)机制主要是甲巯咪唑致肝损伤(MMI-DILI)机制进行综述，以帮助临床医生预判应用甲巯咪唑的可能带来的风险，并为进一步研究MMI-DILI机制提供思路。<br />
Methimazole (MMI) is currently one of the most widely used clinically anti-thyroid drugs, liver inju-ry is the most common adverse reactions, and it is a serious problem for physicians to treat hyper-thyroidism. However, the mechanism of methimazole-induced hepatotoxicity is not fully understood so far. In this paper, the mechanisms of drugs-induced liver injury (DILI) and methimazole-induced liver damage (MMI-DILI) were reviewed, in order to help clinical doctors to predict drugs’ side effect, and provide ideas for further research on mechanism of MMI-DILI.
%K 甲巯咪唑，药物性肝损伤，药物代谢，HLA<br>Methimazole
%K Drugs-Induced Liver Injury (DILI)
%K Drug Metabolism
%K HLA
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=56649